BrainVectis' aim is to develop gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain. Based on work carried out by Nathalie Cartier-Lacave and her team at the UMR1169 unit (INSERM/CEA) and by her collaborators (INSERM/UMR-S 1130, UMR 8246-CNRS), BrainVectis is hosted at MIRCen (CEA, Fontenay aux Roses).
Company Details
- Address
- Paris Brain Institute (Icm) 47 Boulevard De L’hôpital, Paris,75013,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- brainvectis.com
- HQ
- Paris
Brainvectis Questions
Brainvectis's website is brainvectis.com
Brainvectis's LinkedIn profile is https://fr.linkedin.com/company/brainvectis
Brainvectis's industry is
Biotechnology Research
Brainvectis's top competitors are
Nūmi®,
Asfalia Biologics,
Alphaonco,
Askbio Inc.,
Coave Therapeutics,
Spikimm,
Ennodc,
Mitologics,
Adipophyt,
Gleamer.
Brainvectis's categories are Biotechnology Research
